Kynam Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Kynam Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-302,500	Closed	-$21.6M	–	34
2025 Q1	$21.6M	Buy	+302,500	New	+$14.7M	1.82%	17

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Kynam Capital Management's SLNO Position: Q1 2026 in Review

Kynam Capital Management opened a new position in Soleno Therapeutics (SLNO) in Q1 2026: 560,000 shares worth $18.7M. The stake represents 1.16% of the portfolio and ranks #22 among its holdings.

225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Kynam Capital Management held 560,000 shares of Soleno Therapeutics worth $18.7M as of Q1 2026.
Soleno Therapeutics was a new Kynam Capital Management position in Q1 2026.
Soleno Therapeutics made up 1.16% of Kynam Capital Management's portfolio in Q1 2026, its #22 holding.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.